The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer
- PMID: 10760425
- DOI: 10.1016/s0360-3016(99)00018-8
The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer
Abstract
Purpose: It is standard practice in our department to monitor weekly complete blood counts (CBCs) in patients receiving definitive radiation therapy for prostate cancer. The clinical utility and cost effectiveness of this practice has not been analyzed.
Methods and materials: The charts of all prostate cancer patients treated with radiation therapy between January 1994 and July 1996 at the Veterans Administration Hospital, Philadelphia, PA were reviewed. CBC values were available for 89 patients. Patients received a median dose of 68 Gy using a four-field box technique and megavoltage photons. Whole-pelvic radiotherapy followed by a conedown to the prostate was administered to 29 patients. Fifty-nine patients received radiation to the prostate alone or prostate and seminal vesicles. Fifty-seven patients received concurrent hormonal therapy which included luteinizing hormone-releasing hormone (LHRH) agonist, antiandrogens, or both.
Results: No patient experienced a drop in their hemoglobin, white blood cells (WBCs), or platelets below critical nadirs (defined as WBC < 2 counts x 1000/mm(3), hemoglobin < 8 g/dl, platelet < 50 counts x 1000/mm(3) 2 in WBCs. In the urban area surrounding the Philadelphia Veterans Administration Medical Center, the cost of obtaining a CBC is approximately $30. However, if staff time is considered, the cost of obtaining a weekly CBC during prostate cancer radiotherapy approached $400 per patient.
Conclusion: These results suggest that weekly monitoring of CBCs in prostate cancer patients undergoing definitive radiotherapy may not be necessary. We recommend a baseline CBC be performed, and if normal, no other monitoring unless clinically indicated. This strategy would result in a cost savings approaching $30,000 per 100 treated patients. Further research on the cost effectiveness and utility of serial blood tests in patients receiving partial body radiation therapy is needed.
Similar articles
-
Analysis of weekly complete blood counts in patients receiving standard fractionated partial body radiation therapy.Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):617-17. Int J Radiat Oncol Biol Phys. 1995. PMID: 7558950
-
Effect of fractionated regional external beam radiotherapy on peripheral blood cell count.Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):465-72. doi: 10.1016/s0360-3016(00)01587-x. Int J Radiat Oncol Biol Phys. 2001. PMID: 11380235
-
New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.BJU Int. 2012 Aug;110(4):499-504. doi: 10.1111/j.1464-410X.2011.10708.x. Epub 2011 Nov 16. BJU Int. 2012. PMID: 22093775 Clinical Trial.
-
Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):463-71. doi: 10.1016/j.ijrobp.2004.11.041. Int J Radiat Oncol Biol Phys. 2005. PMID: 16168838
-
Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.BJU Int. 2012 Dec;110(11 Pt B):E721-6. doi: 10.1111/j.1464-410X.2012.11536.x. Epub 2012 Sep 27. BJU Int. 2012. PMID: 23016517 Clinical Trial.
Cited by
-
Monitoring of platelet function parameters and microRNA expression levels in patients with prostate cancer treated with volumetric modulated arc radiotherapy.Oncol Lett. 2018 Oct;16(4):4745-4753. doi: 10.3892/ol.2018.9167. Epub 2018 Jul 18. Oncol Lett. 2018. PMID: 30250541 Free PMC article.
-
Cost-effectiveness of universal prophylaxis in pregnancy with prior group B streptococci colonization.Infect Dis Obstet Gynecol. 2009;2009:934698. doi: 10.1155/2009/934698. Epub 2009 Dec 13. Infect Dis Obstet Gynecol. 2009. PMID: 20052397 Free PMC article.
-
Haemoglobin monitoring in endometrial cancer patients undergoing radiotherapy.Clin Transl Oncol. 2017 Dec;19(12):1518-1523. doi: 10.1007/s12094-017-1698-y. Epub 2017 Jun 2. Clin Transl Oncol. 2017. PMID: 28577151
-
Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity.Strahlenther Onkol. 2015 Oct;191(10):771-7. doi: 10.1007/s00066-015-0841-3. Epub 2015 May 26. Strahlenther Onkol. 2015. PMID: 26009493
-
Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study.Radiat Oncol. 2019 Jan 30;14(1):23. doi: 10.1186/s13014-019-1223-2. Radiat Oncol. 2019. PMID: 30700317 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical